ERBB2 and breast cancer: The inability to consistently demonstrate broad clinical benefit with sunitinib and other targeted agents in HER2-negative, but otherwise unselected, populations of patients with advanced breast cancer in recently reported phase III studies highlights the urgent need to identify biomarkers of efficacy to identify specific subsets of patients that do benefit.